New Order. Yesterday, Avivagen announced it entered into a contract for a four tonnes per month recurring order from Meyenberg International, the Company's consultant in Mexico. The contract, which has a term of 18 months, includes an order for 500 kilograms delivered April 30th and a commitment to purchase a minimum of four tonnes per month, commencing July 2021 and ending October 2022. This contract should contribute some $2.4 million of revenue in 2021.Order Momentum. The Meyenberg order continues the order momentum for Avivagen, building off the April 26th announcement that Avivagen received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta Livestock, the largest single shipment purchase order of OxC-beta to date.More to Come? We expect additional orders as successful commercial trials conclude in jurisdictions where OxC-beta Livestock is approved. There are numerous commercial trials currently underway and nearing completion and it our belief the successful conclusion of these trial will help to accelerate the adoption and use of OxC-beta Livestock.Maintaining Outperform. We are maintaining our Outperform rating and US$1.00 12-month price target. Avivagen is an early-stage revenue company focused on developing and commercializing products for livestock, companion animals, and humans. We believe the Company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition. Read More >>